Inhibitors of PI3K–AKT–mTOR, such as rapamycin and LY294002 [38–41], could be evaluated for their potential utility in mouse experiments and clinical trials for treatment of RB patients, and deserved further investigation. This evidence concerns the gene AKT1 and retinoblastoma.